TYP — Tryptamine Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- AU$40.85m
- AU$38.02m
- AU$1.12m
Annual balance sheet for Tryptamine Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 1.74 | 12.7 | 4.85 | 1.64 | 5.37 |
| Net Total Receivables | — | — | 4.19 | 2.78 | 1.4 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4.06 | 17.2 | 9.46 | 4.59 | 7.08 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.84 | 3.48 | 3.25 | 1.01 | — |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 6.54 | 21.5 | 13.6 | 5.88 | 7.45 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.921 | 1.77 | 4.46 | 1.71 | 1.83 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.53 | 2.59 | 4.81 | 1.75 | 1.83 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 5.02 | 18.9 | 8.81 | 4.13 | 5.62 |
| Total Liabilities & Shareholders' Equity | 6.54 | 21.5 | 13.6 | 5.88 | 7.45 |
| Total Common Shares Outstanding |